(Q36682081)

15 August 2017

Muronomab-CD3 for pediatric acute myocarditis (English)

1 reference

15 August 2017

Gregory Perens

1

1 reference

15 August 2017

Daniel S Levi

series ordinal

2

1 reference

15 August 2017

Juan Carlos Alejos

series ordinal

3

1 reference

15 August 2017

Glenn T Wetzel

series ordinal

4

1 reference

15 August 2017

7 December 2006

1 reference

15 August 2017

1 reference

15 August 2017

28

1 reference

15 August 2017

1

1 reference

15 August 2017

21-26

1 reference

https://scigraph.springernature.com/pub.10.1007/s00246-006-1322-3

15 August 2017

0 references

cites work

Prevention and treatment of severe hemodynamic compromise in pediatric heart transplant patients

1 reference

https://api.crossref.org/works/10.1007%2FS00246-006-1322-3

From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-006-1322-3

Susceptibility to myocarditis is dependent on the response of alphabeta T lymphocytes to coxsackieviral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-006-1322-3

Gamma-globulin treatment of acute myocarditis in the pediatric population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00246-006-1322-3

Antiviral therapy for enteroviral infections

21 January 2018

1 reference

12 December 2020

Long term follow up of children with myocarditis treated by immunosuppression and of children with dilated cardiomyopathy

1 reference

12 December 2020

A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators

1 reference

12 December 2020

Combined immunosuppression for the treatment of idiopathic giant cell myocarditis

1 reference

12 December 2020

Immunologic behavior of lymphocytes in experimental viral myocarditis: significance of T lymphocytes in the severity of myocarditis and silent myocarditis in BALB/c-nu/nu mice

1 reference

12 December 2020

The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis

1 reference

12 December 2020

Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation

1 reference

12 December 2020

Reversal of acute fulminant lymphocytic myocarditis with combined technology of OKT3 monoclonal antibody and mechanical circulatory support

1 reference

12 December 2020

1 reference

12 December 2020

Monoclonal antibody therapy for prevention of acute coxsackievirus B3 myocarditis in mice

1 reference

12 December 2020

Long-term prognosis of fulminant myocarditis rescued by percutaneous cardiopulmonary support device.

1 reference

12 December 2020

Anti-CD2 monoclonal antibodies prevent the induction of experimental autoimmune myocarditis

1 reference

12 December 2020

High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis

1 reference

12 December 2020

Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease

1 reference

12 December 2020

Use of OKT3 for acute myocarditis in infants and children

1 reference

12 December 2020

Diagnosis and treatment of pediatric viral myocarditis

1 reference

12 December 2020

Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection

1 reference

12 December 2020

Engineered CD3 antibodies for immunosuppression

1 reference

12 December 2020

Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review

1 reference

12 December 2020

[Acute myocarditis with severe cardiac dysfunction in the pediatric population. The evolution and differential characteristics with respect to adult myocarditis]

1 reference

12 December 2020

Outcomes for children with acute myocarditis

1 reference

12 December 2020

Myocarditis: the Dallas criteria

1 reference

12 December 2020

Giant cell myocarditis in a young man responsive to T-lymphocyte cytolytic therapy.

1 reference

12 December 2020

10.1007/S00246-006-1322-3

Identifiers

DOI

1 reference

15 August 2017

1 reference